Bluebird Bio (BLUE) got here out with a quarterly lack of $23.74 per share versus the Zacks Consensus Estimate of a lack of $6.60. This compares to lack of $15.60 per share a 12 months in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of -259.70%. 1 / 4 in the past, it was anticipated that this biotechnology firm would publish a lack of $7.60 per share when it really produced a lack of $6.20, delivering a shock of 18.42%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
Bluebird
The sustainability of the inventory’s rapid value motion based mostly on the recently-released numbers and future earnings expectations will largely depend upon administration’s commentary on the earnings name.
Bluebird shares have misplaced about 55% for the reason that starting of the 12 months versus the S&P 500’s decline of -2.9%.
What’s Subsequent for Bluebird?
Whereas Bluebird has underperformed the market up to now this 12 months, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There are not any simple solutions to this key query, however one dependable measure that may assist buyers tackle that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis exhibits a robust correlation between near-term inventory actions and traits in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested ranking software just like the Zacks Rank, which has a formidable monitor file of harnessing the facility of earnings estimate revisions.
Forward of this earnings release, the estimate revisions development for Bluebird: combined. Whereas the magnitude and course of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out consistent with the market within the close to future. You possibly can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will probably be fascinating to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$3.60 on $47.2 million in revenues for the approaching quarter and -$15.19 on $282.8 million in revenues for the present fiscal 12 months.
Buyers ought to be conscious of the truth that the outlook for the trade can have a fabric influence on the efficiency of the inventory as effectively. By way of the Zacks Business Rank, Medical – Biomedical and Genetics is at the moment within the prime 28% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
Gilead Sciences (GILD), one other inventory in the identical trade, has but to report outcomes for the quarter ended March 2025. The outcomes are anticipated to be launched on April 24.
This HIV and hepatitis C drugmaker is predicted to publish quarterly earnings of $1.73 per share in its upcoming report, which represents a year-over-year change of +231.1%. The consensus EPS estimate for the quarter has been revised 0.5% larger over the past 30 days to the present stage.
Gilead Sciences’ revenues are anticipated to be $6.8 billion, up 1.7% from the year-ago quarter.
Ought to You Put money into bluebird bio, Inc. (BLUE)?
Earlier than you put money into bluebird bio, Inc. (BLUE), wish to know one of the best shares to purchase for the following 30 days? Take a look at Zacks Funding Analysis for our free report on the 7 best stocks to purchase.
Zacks Funding Analysis has been dedicated to offering buyers with instruments and impartial analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a mean acquire of +24.08% per 12 months. (These returns cowl a interval from January 1, 1988 by way of Might 6, 2024.)
bluebird bio, Inc. (BLUE) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
